We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+29.97%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$752M
AUM Growth
+$105M
Cap. Flow
-$17.7M
Cap. Flow %
-2.36%
Top 10 Hldgs %
46.3%
Holding
87
New
16
Increased
20
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$16.7M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$16M
3
DVAX
Dynavax Technologies
DVAX
+$10.9M
4
NVRO
NEVRO CORP.
NVRO
+$10.2M
5
CHRS icon
Coherus Oncology
CHRS
+$8.85M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$39.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$29.6M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$28.1M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$27.1M
5
CMRX
Chimerix, Inc.
CMRX
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 88.18%
2 Miscellaneous 11.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGLS
26
DELISTED
Regulus Therapeutics
RGLS
$9.83M 1.31%
7,471
– –
FWP
27
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$9.7M 1.29%
36,429
– –
CRIS icon
28
Curis
CRIS
$2.76M
$8.71M 1.16%
1,316
– –
KERX
29
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$8.24M 1.1%
826,000
– –
KPTI icon
30
Karyopharm Therapeutics
KPTI
$38.1M
$8.19M 1.09%
20,066
– –
COLL icon
31
Collegium Pharmaceutical
COLL
$725M
$8.03M 1.07%
+450,000
New +$7.78M
TPST icon
32
Tempest Therapeutics
TPST
$20.3M
$7.3M 0.97%
86
-72
-46% -$6.6M
OMER icon
33
Omeros
OMER
$1.27B
$6.99M 0.93%
388,500
– –
NERV icon
34
Minerva Neurosciences
NERV
$168M
$6.64M 0.88%
143,132
+2
+0% +$85
EPZM
35
DELISTED
Epizyme, Inc
EPZM
$6.39M 0.85%
266,250
– –
XLRN
36
DELISTED
Acceleron Pharma
XLRN
$6.33M 0.84%
200,000
+30,000
+18% +$968K
ARRY
37
DELISTED
Array Biopharma Inc
ARRY
$6.13M 0.81%
850,000
– –
LPCN icon
38
Lipocine
LPCN
$18M
$5.72M 0.76%
39,216
– –
APTO
39
DELISTED
Aptose Biosciences, Inc.
APTO
$5.54M 0.74%
2,404
– –
RMTI icon
40
Rockwell Medical
RMTI
$31.8M
$5.48M 0.73%
3,091
– –
EPRS
41
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$5.12M 0.68%
896,600
– –
NKTR icon
42
Nektar Therapeutics
NKTR
$2.27B
$4.97M 0.66%
26,500
– –
IOVA icon
43
Iovance Biotherapeutics
IOVA
$4.4B
$4.58M 0.61%
499,815
+75,000
+18% +$837K
KITE
44
DELISTED
Kite Pharma, Inc.
KITE
$4.2M 0.56%
68,800
-31,200
-31% -$1.78M
SGMO
45
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4M 0.53%
361,000
-81,000
-18% -$1.04M
IMDZ
46
DELISTED
Immune Design Corp.
IMDZ
$3.9M 0.52%
189,000
+70,000
+59% +$1.65M
CYAD
47
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$3.9M 0.52%
+75,000
New +$4.03M
CBIO
48
Crescent Biopharma
CBIO
$652M
$3.65M 0.49%
4,590
– –
TLPH icon
49
Talphera
TLPH
$61.8M
$3.6M 0.48%
42,500
– –
DRNA
50
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.42M 0.45%
245,000
+75,000
+44% +$1.38M
1
2
3 4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q2 2015 Portfolio in Review

As of Q2 2015, Cormorant Asset Management held 87 positions worth $752M, up 16% from $647M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management's Q2 2015 filing shows 16 new, 20 increased, 11 reduced and 7 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 140,000 shares worth $16.8M. The largest sale was Puma Biotechnology, an estimated $39.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

  • Cormorant Asset Management's largest Q2 2015 buy was Alnylam Pharmaceuticals: 140,000 shares worth $16.8M.
  • Cormorant Asset Management added most to Alder Biopharmaceuticals in Q2 2015, an estimated $16M increase.
  • Cormorant Asset Management's biggest Q2 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $28.1M.
  • Cormorant Asset Management fully exited Puma Biotechnology in Q2 2015, selling an estimated $39.5M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $752M portfolio in Q2 2015.
  • Cormorant Asset Management opened 16 new positions and closed 7 in Q2 2015.
  • Cormorant Asset Management's portfolio value rose 16% quarter-over-quarter to $752M.

Based on Cormorant Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.